Highly sensitive detection of melanoma based on serum proteomic profiling

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 9, 2009, Pages 1257-1264

  Caron, Julie ^a,c   Mangé, Alain ^b,c,d   Guillot, Bernard ^a,c   Solassol, Jérôme ^b,c  

^a HÔPITAL SAINT ELOI   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE VAL D AURELLE   (France)

Author keywords

Cancer; Markers; Mass spectrometry; Melanoma; Proteomics

Indexed keywords

PROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; ARTIFICIAL NEURAL NETWORK; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRAINING; VALIDATION STUDY; VOLUNTEER;

BLOOD PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEURAL NETWORKS (COMPUTER); PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 68649102756     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0567-7     Document Type: Article

References (25)

1. CM Balch AC Buzaid SJ Soong MB Atkins N Cascinelli DG Coit ID Fleming JE Gershenwald A Houghton Jr JM Kirkwood KM McMasters MF Mihm DL Morton DS Reintgen MI Ross A Sober JA Thompson JF Thompson 2001 Final version of the American Joint Committee on cancer staging system for cutaneous melanoma J Clin Oncol 19 16 3635 3648
2. S Brennecke M Deichmann H Naeher H Kurzen 2005 Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma Melanoma Res 15 6 515 522 10.1097/00008390-200512000-00006 (Pubitemid 44124263)
3. E Caputo ML Lombardi V Luongo R Moharram P Tornatore G Pirozzi J Guardiola BM Martin 2005 Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques J Chromatogr B Analyt Technol Biomed Life Sci 819 1 59 66 10.1016/j.jchromb.2005.01.022 (Pubitemid 41583162)
4. LH Cazares JI Diaz RR Drake OJ Semmes 2008 MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers Methods Mol Biol 428 125 140 10.1007/978-1-59745-117-8-7
5. M Deichmann A Benner M Bock A Jackel K Uhl V Waldmann H Naher 1999 S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on cancer stage IV melanoma J Clin Oncol 17 6 1891 1896
6. ET Fung GL Wright Jr EA Dalmasso 2000 Proteomic strategies for biomarker identification: progress and challenges Curr Opin Mol Ther 2 6 643 650
7. C Garbe U Leiter U Ellwanger HJ Blaheta F Meier G Rassner B Schittek 2003 Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients Cancer 97 7 1737 1745 10.1002/cncr.11250 (Pubitemid 36350717)
8. F Girosi 1998 An equivalence between sparse approximation and support vector machines Neural Comput 10 6 1455 1480 10.1162/089976698300017269
9. R Harpio R Einarsson 2004 S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma Clin Biochem 37 7 512 518 10.1016/j.clinbiochem. 2004.05.012 (Pubitemid 38845014)
10. T Kageshita A Yoshii T Kimura N Kuriya T Ono M Tsujisaki K Imai S Ferrone 1993 Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma Cancer Res 53 20 4927 4932
11. ML Lee W Lu GA Whitmore D Beier 2002 Models for microarray gene expression data J Biopharm Stat 12 1 1 19 10.1081/BIP-120005737 (Pubitemid 34786909)
12. L Li H Tang Z Wu J Gong M Gruidl J Zou M Tockman RA Clark 2004 Data mining techniques for cancer detection using serum proteomic profiling Artif Intell Med 32 2 71 83 10.1016/j.artmed.2004.03.006 (Pubitemid 39201347)
13. S Mian S Ugurel E Parkinson I Schlenzka I Dryden L Lancashire G Ball C Creaser R Rees D Schadendorf 2005 Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients J Clin Oncol 23 22 5088 5093 10.1200/JCO.2005.03.164 (Pubitemid 46224016)
14. T Moller H Anderson T Aareleid T Hakulinen H Storm L Tryggvadottir I Corazziari E Mugno 2003 Cancer prevalence in Northern Europe: the EUROPREVAL study Ann Oncol 14 6 946 957 10.1093/annonc/mdg255 (Pubitemid 36827212)
15. EF Petricoin AM Ardekani BA Hitt PJ Levine VA Fusaro SM Steinberg GB Mills C Simone DA Fishman EC Kohn LA Liotta 2002 Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 9306 572 577 10.1016/S0140-6736(02) 07746-2 (Pubitemid 34178440)
16. AJ Rai PM Stemmer Z Zhang BL Adam WT Morgan RE Caffrey VN Podust M Patel LY Lim NV Shipulina DW Chan OJ Semmes HC Leung 2005 Analysis of human proteome organization plasma proteome project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers Proteomics 5 13 3467 3474 10.1002/pmic.200401320 (Pubitemid 41192051)
17. OJ Semmes Z Feng BL Adam LL Banez WL Bigbee D Campos LH Cazares DW Chan WE Grizzle E Izbicka J Kagan G Malik D McLerran JW Moul A Partin P Prasanna J Rosenzweig LJ Sokoll S Srivastava I Thompson MJ Welsh N White M Winget Y Yasui Z Zhang L Zhu 2005 Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility Clin Chem 51 1 102 112 10.1373/clinchem.2004.038950 (Pubitemid 40024018)
18. MN Sirott DF Bajorin GY Wong Y Tao PB Chapman MA Templeton AN Houghton 1993 Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis Cancer 72 10 3091 3098 10.1002/1097-0142(19931115)72: 10<3091::AID-CNCR2820721034>3.0.CO;2-V
19. J Solassol P Marin E Demettre P Rouanet J Bockaert T Maudelonde A Mange 2005 Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection Anal Biochem 338 1 26 31 10.1016/j.ab.2004.11.031 (Pubitemid 40228894)
20. J Solassol W Jacot L Lhermitte N Boulle T Maudelonde A Mange 2006 Clinical proteomics and mass spectrometry profiling for cancer detection Expert Rev Proteomics 3 3 311 320 10.1586/14789450.3.3.311 (Pubitemid 43979405)
21. J Stahlecker A Gauger A Bosserhoff R Buttner J Ring R Hein 2000 MIA as a reliable tumor marker in the serum of patients with malignant melanoma Anticancer Res 20(6D) 5041 5044
22. S Ugurel G Rappl W Tilgen U Reinhold 2001 Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival J Clin Oncol 19 2 577 583
23. K Wakamatsu T Kageshita M Furue N Hatta Y Kiyohara J Nakayama T Ono T Saida M Takata T Tsuchida H Uhara A Yamamoto N Yamazaki A Naito S Ito 2002 Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience Melanoma Res 12 3 245 253 10.1097/00008390-200206000-00008 (Pubitemid 34666815)
24. LL Wilson L Tran DL Morton DS Hoon 2004 Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry Ann NY Acad Sci 1022 317 322 10.1196/annals.1318.047 (Pubitemid 38951619)
25. Z Zhang Y Yu F Xu A Berchuck C van Haaften-Day LJ Havrilesky HW de Bruijn AG van der Zee RP Woolas IJ Jacobs S Skates DW Chan RC Bast Jr 2007 Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer Gynecol Oncol 107 3 526 531 10.1016/j.ygyno.2007.08.009 (Pubitemid 350160868)